Haw ParHAWPF 96 9-Day RSI is 7.76 as of Jul. 06, 2026. GuruFocus rates HAWPF with a GF Score™ of 96/100 and a GF Value™ of $8.90. The stock has 3 warning signs investors should review. Among 1,047 Drug Manufacturers companies, Haw Par ranks better than 63.32% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-06), Haw Par's 9-Day RSI is 7.76.
The industry rank for Haw Par's 9-Day RSI or its related term are showing as below:
HAWPF's 9-Day RSI is ranked better than 63.32% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 54.19
vs HAWPF: 7.76
Haw Par (OTCPK:HAWPF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Haw Par 9-Day RSI Related Terms
HAWPF vs LLY, JNJ, ABBV: 9-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Haw Par's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Haw Par's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a 9-Day RSI of 7.76 as of Jul. 06, 2026. According to the industry distribution chart, Haw Par ranks #384 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 36.7%.
Is Haw Par's 9-Day RSI too high?
Haw Par's current 9-Day RSI is 7.76. The Drug Manufacturers industry median 9-Day RSI is 54.19. Haw Par's value of 7.76 is 85.7% below this industry median. Based on the distribution chart, Haw Par ranks #384 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Haw Par has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's 9-Day RSI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #384 out of 1047 companies for 9-Day RSI. This puts Haw Par in the upper half of its industry. The industry median 9-Day RSI is 54.19. Haw Par's value of 7.76 is 85.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 54.19, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current 9-Day RSI of 7.76 is 85.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 54.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current 9-Day RSI is 7.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current 9-Day RSI of 7.76. The stock's GF Value™ is $8.90, compared to a current price of $12.00 — trading 34.8% above its estimated fair value. The current 9-Day RSI is 7.76 and 85.7% below the Drug Manufacturers industry median of 54.19. Haw Par's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Haw Par (HAWPF), the current 9-Day RSI is 7.76 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 34.8% above its estimated GF Value™ of $8.90.
Key valuation signals for HAWPF:
9-Day RSI: 7.76
GF Value™: $8.90 vs. price of $12.00 (34.8% above fair value)
Industry Position: 85.7% below the Drug Manufacturers median (#384 of 1047)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
96GF Score
Get the complete analysis for HAWPF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 